News | November 28, 2024
Granules' net zero commitment approved by SBTi
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
The product will be marketed by Dr. Reddy's
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Subscribe To Our Newsletter & Stay Updated
